Precision BioSciences Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 3/6

Precision BioSciences şirketinin toplam hissedar öz sermayesi $64.9M ve toplam borcu $22.3M olup, bu da borç-öz sermaye oranını 34.3% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $153.3M ve $88.4M dir.

Anahtar bilgiler

34.3%

Borç/özkaynak oranı

US$22.28m

Borç

Faiz karşılama oranı	n/a
Nakit	US$101.20m
Eşitlik	US$64.87m
Toplam yükümlülükler	US$88.39m
Toplam varlıklar	US$153.26m

Son finansal sağlık güncellemeleri

Recent updates

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: PBS0 'nin kısa vadeli varlıkları ( $110.5M ) kısa vadeli yükümlülüklerini ( $12.0M ) aşıyor.

Uzun Vadeli Yükümlülükler: PBS0 şirketinin kısa vadeli varlıkları ( $110.5M ) uzun vadeli yükümlülüklerini ( $76.4M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: PBS0 şirketinin toplam borcundan daha fazla nakiti var.

Borcun Azaltılması: PBS0 şirketinin borç/öz sermaye oranı son 5 yılda 0% seviyesinden 34.3% seviyesine yükseldi.

Borç Kapsamı: PBS0 'nin işletme nakit akışı negatif olduğundan borçlar iyi karşılanamıyor.

Faiz Kapsamı: PBS0 şirketinin borçlarına ilişkin faiz ödemelerinin EBIT tarafından iyi bir şekilde karşılanıp karşılanmadığını belirlemek için yeterli veri yok.

Precision BioSciences Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 3/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Precision BioSciences Receives Approval from The Nasdaq Stock Market LLC to Transfer the Listing of its Common Stock from the Nasdaq Global Select Market to the Nasdaq Capital Market

Recent updates

Precision BioSciences, Inc. to Report Q3, 2024 Results on Nov 04, 2024

Precision BioSciences Receives First Approval of Clinical Trial Application to Initiate PBGENE-HBV First-In-Human Study for the Treatment of Chronic Hepatitis B

Precision BioSciences, Inc Announces Executive Changes Changes

Precision BioSciences, Inc. to Report Q2, 2024 Results on Aug 01, 2024

Precision Biosciences, Inc. Presents New Preclinical Safety Data for Pbgene-Hbv Clinical Candidate At the European Association for the Study of the Liver Congress

Precision BioSciences, Inc. to Report Q1, 2024 Results on May 13, 2024

Precision BioSciences, Inc., Annual General Meeting, Jun 04, 2024

Precision BioSciences, Inc. to Report Q4, 2023 Results on Mar 27, 2024

Precision BioSciences Announces MHRA Approval for Partner iECURE to Expand Phase 1/2 Clinical Trial of ARCUS Gene Editing Program in OTC Deficiency

Precision BioSciences, Inc. has filed a Follow-on Equity Offering.

Precision BioSciences, Inc. has filed a Follow-on Equity Offering.

Precision BioSciences, Inc. Receives Pre-IND Feedback from US FDA for PBGENE-HBV as It Advances Towards Clinical Readiness

Precision BioSciences, Inc. announced that it expects to receive funding from TG Therapeutics, Inc.

Precision Biosciences Announces Approval of First Clinical Trial Application of Arcus Gene Insertion Program by Partner iEcure

Precision BioSciences, Inc. Announces Publication in Nature Metabolism Supporting ARCUS In Vivo Gene Editing as a Potentially Curative Treatment for Mitochondrial Diseases

Precision BioSciences, Inc. Presents Late-Breaking Data Highlighting Preclinical Efficacy and Safety of PBGENE-HBV for Chronic Hepatitis B at AASLD’s The Liver Meeting 2023

Precision BioSciences, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Precision BioSciences Receives Approval from The Nasdaq Stock Market LLC to Transfer the Listing of its Common Stock from the Nasdaq Global Select Market to the Nasdaq Capital Market

Precision BioSciences, Inc. Announces Management Changes

Second quarter 2023 earnings released: US$0.10 loss per share (vs US$0.46 loss in 2Q 2022)

Precision BioSciences, Inc. to Report Q2, 2023 Results on Aug 04, 2023

Precision Biosciences, Inc. Provides Updates on Azer-Cel FDA Meeting, Potential Partnerships and Timing of in Vivo R&D Day

Precision Biosciences, Inc. Announces Oral Presentation of Positive Arcus Gene Editing Data At International Liver Congress 2023

Precision Biosciences, Inc. Presents Preclinical Data Demonstrating Potential of ARCUS for Treatment of Duchenne Muscular Dystrophy at American Society of Gene & Cell Therapy 26th Annual Meeting

First quarter 2023 earnings released: US$0.23 loss per share (vs US$0.46 loss in 1Q 2022)

No longer forecast to breakeven

Full year 2022 earnings released: US$1.27 loss per share (vs US$0.52 loss in FY 2021)

No longer forecast to breakeven

Precision BioSciences Receives Favorable Type C Feedback from the FDA on the Company’s Chemistry, Manufacturing, and Controls (CMC) Strategies for Late-Stage Development of Azercabtagene Zapreleucel, Its Lead Allogeneic Car T Clinical Candidate

Precision BioSciences, Inc. Presents Analysis of Azer-Cel, Allogeneic CAR T Product Attributes Related to In Vivo Pharmacokinetics, Pharmacodynamics, and Clinical Outcomes at 2022 American Society of Hematology Annual Meeting

Less than half of directors are independent

Precision BioSciences, Inc. Announces Raymond Schinazi Resigns from Board and as Chair of Nominating and Corporate Governance Committee and Member of Compensation Committee and Science and Technology Committee

Third quarter 2022 earnings released: US$0.22 loss per share (vs US$0.19 loss in 3Q 2021)

Precision BioSciences, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Chief Financial Officer recently bought €61k worth of stock

Precision BioSciences, Inc Announces Executive Promotions

Second quarter 2022 earnings released: US$0.46 loss per share (vs US$0.38 profit in 2Q 2021)

Precision BioSciences, Inc. to Report Q2, 2022 Results on Aug 08, 2022

Precision BioSciences, Inc. has completed a Follow-on Equity Offering in the amount of $50.000001 million.

Precision BioSciences, Inc.(NasdaqGS:DTIL) dropped from Russell 2000 Dynamic Index

Precision BioSciences, Inc. Provides Update on Allogeneic CAR T Programs and Path Forward with Its Lead PBCAR0191 Candidate for CAR T Relapsed Patient Population

Precision Biosciences, Inc. Appoints Melinda Brown to its Board of Directors and Chair of the Board’s Audit Committee

Precision BioSciences, Inc. Appoints Juli Blanche as Chief People Officer

First quarter 2022 earnings released: US$0.46 loss per share (vs US$0.33 loss in 1Q 2021)

Precision BioSciences, Inc. to Report Q1, 2022 Results on May 09, 2022

High number of new directors

Precision BioSciences, Inc. Announces Shalini Sharp Will Not Seek Re-Election to the Board of Directors

Precision BioSciences, Inc., Annual General Meeting, May 10, 2022

Precision BioSciences, Inc., Annual General Meeting, May 10, 2022

Chief Financial Officer recently bought €46k worth of stock

Chief Financial Officer recently bought €46k worth of stock

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Precision BioSciences, Inc. Reports Clinical Program Updates for Its Allogeneic Car T Pipeline

Third quarter 2021 earnings released: US$0.19 loss per share (vs US$0.50 loss in 3Q 2020)

Second quarter 2021 earnings released: EPS US$0.38 (vs US$0.63 loss in 2Q 2020)

Chief Operating Officer David Thomson has left the company

Precision BioSciences Doses First Patient in Phase 1 Allogeneic CAR T Clinical Trial of PBCAR19B Immune Evading Stealth Cell for Relapsed/Refractory Non-Hodgkin Lymphoma

Precision BioSciences, Inc.(NasdaqGS:DTIL) dropped from Russell Microcap Value Index

Precision Biosciences, Inc. Provides Updates Interim Clinical Results from Its Phase 1/2A Study of PBCAR0191

Precision BioSciences, Inc. Publishes New Study in Nature Communications Using Engineered Arcus Nuclease to Target Mutant Mitochondrial DNA in Vivo

Co-Founder recently sold €154k worth of stock

Forecast to breakeven in 2025

First quarter 2021 earnings released: US$0.33 loss per share (vs US$0.52 loss in 1Q 2020)

Independent Director has left the company

Precision Biosciences, Inc. Announces New Preclinical Data Presented at the 2021 American Society of Genetic & Cell Therapy Annual Meeting Highlights Precision Biosciences’ Arcus in Vivo Genome Editing

Precision BioSciences Announces Paper Presentation at the Association for Research in Vision and Ophthalmology 2021 Annual Meeting

Full year 2020 earnings released: US$2.10 loss per share (vs US$2.21 loss in FY 2019)

Precision BioSciences, Inc. to Report Q4, 2020 Results on Mar 18, 2021

Precision BioSciences, Inc. Announces 3-Year Pre-Clinical Study Results Showing Long-Term Durability and Safety of ARCUS in Vivo Gene Editing to Cut LDL Cholesterol Levels in Nonhuman Primates

New 90-day high: €13.00

Precision BioSciences Announces FDA Accepts IND for PBCAR19B, a Next-Generation, Stealth Cell, CD19 Allogeneic CAR T Candidate for Non-Hodgkin Lymphoma

New 90-day high: €11.40

Precision BioSciences Announces Closing of in Vivo Gene Editing Collaboration and License Agreement with Eli Lilly and Company

Precision BioSciences, Inc. Announces Shane Barton to Serve as Interim Principal Accounting Officer